Bryan Neth, MD, PhD (@bryanneth) header
Bryan Neth, MD, PhD (@bryanneth) profile picture

Neuro-Oncology + Behavioral Neurology @mayoclinic | @mayoneurores + @WakeForest + @floridastate alum | Science. Art. Flavor. | Views are my own

Minnesota, USA
Joined October 2011
Photo by Bryan Neth, MD, PhD (@bryanneth)Photo by Bryan Neth, MD, PhD (@bryanneth)Photo by Bryan Neth, MD, PhD (@bryanneth)Photo by Bryan Neth, MD, PhD (@bryanneth)Photo by Bryan Neth, MD, PhD (@bryanneth)Photo by Bryan Neth, MD, PhD (@bryanneth)
Bryan Neth, MD, PhD retweeted
In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2. Full study results: nej.md/4Agtyhz
3
51
11
168
52,759
Bryan Neth, MD, PhD retweeted
Click anywhere on the brain and see that region's projections. Fibers are diffusion tractography (dMRI) from Human Connectome Project amyleesterling.github.io/hum…
17
166
18
668
43,863
Bryan Neth, MD, PhD retweeted
🚨🚨Randomized Trial: How does Hypofraction compare to Standard of Care Stupp regimen for GBM? POORLY, according to the Gold trial with worse OS and increased radiation necrosis thegreenjournal.com/article/…
6
23
3
65
5,295
Bryan Neth, MD, PhD retweeted
The recommendation to perform serum SPEP with immunofixation in every case of distal symmetric polyneuropathy has caused unnecessary harm to patients. This advice has been repeated so often that many regard it as an absolute truth. However, Dr. Go and colleagues from @MayoClinic Hematology demonstrate the very low clinical utility of monoclonal gammopathy testing in patients with peripheral neuropathy. link.springer.com/article/10…
5
30
4
117
31,169
Bryan Neth, MD, PhD retweeted
🚨 Out today in Cell! @CellCellPress Path2Space: #AI that predicts spatial transcriptomics (ST) from H&E pathology, enabling spatial biomarker discovery in #BreastCancer at scale. 📄 doi.org/10.1016/j.cell.2026.… 🧵1/8
7
106
4
355
216,489
Bryan Neth, MD, PhD retweeted
Our paper in @Nature today 🥳 We tracked 6,438 mice from puberty to death and mapped the genetics of *when* you die, not just whether a gene associates with lifespan. nature.com/articles/s41586-0… 59 loci. Two decades of data. Thread 👇 #Longevity #Aging #Genetics #Healthspan
16
279
26
1,229
123,726
Bryan Neth, MD, PhD retweeted
Honored to have a @NatRevClinOncol publication on the work we & colleagues have done on #meningiomas Research & discoveries improving #care #clinicaltrials @ICOMeningioma @MeningiomaBot RT 🙏🏻 @mayoclinic @MayoRadOnc @MayoCancerCare @MayoClinicNeuro Thanking all #collaborators
New online! Multidisciplinary management of meningiomas in the era of precision oncology dlvr.it/TS17pK
1
3
1
30
2,928
Bryan Neth, MD, PhD retweeted
Why do only some cancer patients develop #paraneoplastic neurological syndromes (PNS)? 🧠 This review explores the immune mechanisms behind PNS and how tumor genetics & immune tolerance shape risk. Kudos to @AKunchok. Open access link: journals.lww.com/co-neurolog…
1
29
70
4,398
Bryan Neth, MD, PhD retweeted
Should we treat higher SRS doses for brainstem mets (than the typical lower doses used)? Tumor control probability MODELING: 1 Yr 90%LC 18.9 Gy/1, 25.7/3, 28.6/5 2 Yr 90%LC 20.5 Gy/1, 28.2/3, 31.5/5 sciencedirect.com/science/ar…
1
27
2
82
9,178
Bryan Neth, MD, PhD retweeted
Editorial CATNON IDHmt Grade 3 Astrocytoma · NO benefit concurrent temozolomide · Sig benefit w/adjuvant TMZ · MGMT NOT prognostic · Poor prog CDKN2A/B homo deletion, PDGFRA amp, methy profile academic.oup.com/neuro-oncol…
1
29
77
3,785
Bryan Neth, MD, PhD retweeted
What is the long term control Sporadic Vestibular Schwannoma after radiosurgery? LC 5, 10, & 15 years 96%, 92%, & 91% 13% pseudoprogression median time 0.5 yrs (only 4% >5yr after SRS) doi.org/10.3171/2025.8.JNS25…
2
7
24
1,240
Bryan Neth, MD, PhD retweeted
For decades, researchers have noted that cancer and Alzheimer’s disease are rarely found in the same person go.nature.com/4qIHwo2
50
497
149
3,693
2,638,363
Gonzalez-Aponte et al. reported circadian rhythms in MGMT promoter methylation and protein levels in GBM, with peaks at midday and CT4, respectively, predicting time-of-day differences in temozolomide efficacy. #JNO Read more:link.springer.com/article/10…
7
1
10
1,603
Bryan Neth, MD, PhD retweeted
A decade after our world-first BBB opening for #GBM, our newest trial shows FUS is safe, well-tolerated, with signals of benefit. A major milestone for a devastating illness. Grateful to @INSIGHTEC, @FUSFoundation, our donors, and brave patients. sciencedirect.com/science/ar…
1
17
57
5,848
Bryan Neth, MD, PhD retweeted
Coming soon, our first ever issue dedicated to…
4
17
4
254
13,582